exploring the drug's significant bronchodilator
These two clinical trials are part of the Company's five-study Phase 2b program that included three previously completed, randomized, double-blind trials: one dose-ranging trial each of PT005 and PT001, plus a placebo- and active-controlled study of PT003 compared with its components and marketed bronchodilators
, Foradil[R] Aerolizer[R] and Spiriva[R] HandiHaler[R].
In addition, we observed a pronounced bronchodilator
response with RPL554 in asthmatics that is similar to the bronchodilation we recently reported in COPD patients.
This completes the first bronchodilator
study in mild to moderate COPD patients at the Tor Vergata Clinic in Rome and is an expansion of the pilot part of the study announced by the Company on 10 November 2011.
The primary objective of this study is to evaluate whether RPL554 has an additive bronchodilator
effect and is well tolerated in COPD patients, when administered in addition to standard of care bronchodilators
Assesses inhalation device technology for delivering bronchodilators
orally, and evaluates product technology issues and evolving market factors
If this does not help relieve symptoms, your GP may recommend a long-acting bronchodilator
inhaler, which works in a similar way but lasts for at least 12 hours.
Significantly increased risks were noted for any bronchodilator
use (without an additional anti-inflammatory drug) and cleft lip alone (adjusted odds ratio, 1.
We have identified compounds that are more potent than our previously identified set of compounds, paving the way for development of bronchodilators
for treating asthma and COPD," said study author Kathryn Robinett, pulmonary and critical care fellow at the University of Maryland School of Medicine.
The general indication for use of an adrenergic bronchodilator
is relaxation of airway smooth muscle in the presence of reversible airflow obstruction associated with acute and chronic asthma (including exercise-induced asthma), bronchitis, emphysema, bronchiectasis, and other obstructive airway diseases.
In moderate to moderately severe disease (FEV, between 50 and 80% of predicted), the regular use of a long-acting bronchodilator
Theophylline is a nonspecific phosphodiesterase inhibitor and has bronchodilator
effects at higher doses, where there is a higher risk of toxicity.
In particular, ICS treatment should be used to augment regular bronchodilator
treatment for patients with advanced disease and repeated exacerbations.
The most commonly used bronchodilator
in the United States is albuterol (Ventolin, Proventil, ProAir, generic albuterol), and the preferred method of taking bronchodilators
is through inhalation with a metered dose inhaler.
Properly administered bronchodilator
therapy can help differentiate between asthma and other conditions with similar symptoms such as pneumonia, emphysema, and congestive heart failure.